Representation of Women and Pregnant Women in HIV Research: A Limited Systematic Review

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Westreich, Daniel ^a,b   Rosenberg, Molly ^a   Schwartz, Sheree ^a   Swamy, Geeta ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ARTICLE; COHORT ANALYSIS; EXPERIMENTAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREGNANCY; PREGNANT WOMAN;

BIOMEDICAL RESEARCH; FEMALE; HIV INFECTIONS; HUMANS; JOURNAL IMPACT FACTOR; PERIODICALS AS TOPIC; PREGNANCY; PREGNANT WOMEN; SEX FACTORS;

EID: 84883012686     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073398     Document Type: Article

References (60)

1. UNAIDS (2008) 2008 Report on the global AIDS epidemic. Available: http://wwwunaidsorg/en/KnowledgeCentre/HIVData/GlobalReport/2008/. Geneva.
2. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, et al. (2005) Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS 19: 1525-1534. doi:10.1097/01.aids.0000183129.16830.06. PubMed: 16135907.
3. UNAIDS/WHO (2007). ids Epidemic Update: 2007. Geneva.
4. Myer L, Carter RJ, Katyal M, Toro P, El-Sadr WM, et al. (2010) Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLOS Med 7: e1000229. PubMed: 20161723.
5. Schwartz S, Mehta S, Taha T, Rees H, Venter F, et al. (2011) High Pregnancy Intentions and Missed Opportunities for Patient-Provider Communication About Fertility in a South African Cohort of HIV-Positive Women on Antiretroviral Therapy. AIDS Behav.
6. Westreich D, Maskew M, Rubel D, MacDonald P, Jaffray I, et al. (2012) Incidence of pregnancy after initiation of antiretroviral therapy in South Africa: a retrospective clinical cohort analysis. In press at Infectious Diseases in Obstetrics & Gynecology. PubMed: 22778536.
7. Schwartz SR, Rees H, Mehta S, Venter WD, Taha TE, et al. (2012) High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLOS ONE 7: e36039. doi:10.1371/journal.pone.0036039. PubMed: 22558319.
8. Karim QA, Kharsany AB, Frohlich JA, Werner L, Mashego M, et al. (2011) Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol 40: 922-930. doi:10.1093/ije/dyq176. PubMed: 21047913.
9. Chi BH, Sinkala M, Stringer EM, Cantrell RA, Mtonga V, et al. (2007) Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 21: 957-964. doi:10.1097/QAD.0b013e32810996b2. PubMed: 17457089.
10. Coffie PA, Ekouevi DK, Chaix ML, Tonwe-Gold B, Clarisse AB, et al. (2008) Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Clin Infect Dis 46: 611-621. doi:10.1086/526780. PubMed: 18197758.
11. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P,et al (2004) Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351: 229-240. doi:10.1056/NEJMoa041305. PubMed: 15247339.
12. Westreich D, Eron J, Behets F, Horst Cv, Van Rie A, (2007) Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. J Infect Dis 195: 837-846. doi:10.1086/511276. PubMed: 17299714.
13. MacCarthy S, Laher F, Nduna M, Farlane L, (2009) Responding to Her Question: A Review of the Influence of Pregnancy on HIV Disease Progression in the Context of Expanded Access to HAART in Sub-Saharan Africa. AIDS Behav, 13 (Suppl 1):: 66-71. PubMed: 19301115.
14. van Hasselt JG, Andrew MA, Hebert MF, Tarning J, Vicini P, et al. (2012) The Status of Pharmacometrics in Pregnancy: Highlights from the 3(rd) American Conference on Pharmacometrics. Br J Clin Pharmacol, 74: 932-9. PubMed: 22452385.
15. Mirochnick M, Capparelli E, (2004) Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 43: 1071-1087. doi:10.2165/00003088-200443150-00002. PubMed: 15568888.
16. Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C, et al. (2011) Pregnancy and virologic response to antiretroviral therapy in South Africa. PLOS ONE 6: e22778. doi:10.1371/journal.pone.0022778. PubMed: 21829650.
17. French R, Brocklehurst P, (1998) The effect of pregnancy on survival in women infected with HIV: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 105: 827-835. doi:10.1111/j.1471-0528.1998.tb10226.x. PubMed: 9746374.
18. Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, et al. (2007) Pregnancy and HIV Disease Progression during the Era of Highly Active Antiretroviral Therapy. J Infect Dis 196: 1044-1052. doi:10.1086/520814. PubMed: 17763327.
19. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, et al. (2005) Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366: 1182-1188. doi:10.1016/S0140-6736(05)67481-8. PubMed: 16198767.
20. Mugo NR, Heffron R, Donnell D, Wald A, Were EO, et al. (2011) Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 25: 1887-1895. doi:10.1097/QAD.0b013e32834a9338. PubMed: 21785321.
21. Morrison CS, Wang J, Van Der Pol B, Padian N, Salata RA, et al. (2007) Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS 21: 1027-1034. doi:10.1097/QAD.0b013e3280f00fc4. PubMed: 17457097.
22. National Institutes of Health (2001) NIH Policy and Guidelines on the inclusion of women and minorities as subjects in Clinical Research - Amended, October (2001). MD: Bethesda.
23. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED, (2001) Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 286: 708-713. doi:10.1001/jama.286.6.708. PubMed: 11495621.
24. Foulkes MA, (2011) After inclusion, information and inference: reporting on clinical trials results after 15 years of monitoring inclusion of women. J Womens Health (Larchmt) 20: 829-836. doi:10.1089/jwh.2010.2527.
25. Weinberger AH, McKee SA, Mazure CM, (2010) Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J Womens Health (Larchmt) 19: 1727-1732. doi:10.1089/jwh.2009.1784. PubMed: 20799923.
26. Berlin JA, Ellenberg SS, (2009) Inclusion of women in clinical trials. BMC Med 7: 56. doi:10.1186/1741-7015-7-56. PubMed: 19818115.
27. Macklin R, (2010) Enrolling pregnant women in biomedical research. Lancet 375: 632-633. doi:10.1016/S0140-6736(10)60257-7. PubMed: 20198725.
28. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. (2007) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 18: 800-804. doi:10.1097/EDE.0b013e3181577654. PubMed: 18049194.
29. ISI (2010) Web of Knowledge. J Citation Rep Science. (Accessed April 30 2012). Thomson: Reuters, New York.
30. Chaiyachati K, Hirschhorn LR, Tanser F, Newell ML, Bärnighausen T, (2011) Validating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South Africa. AIDS Patient Care STDs 25: 163-170. PubMed: 21269131.
31. da Silva GK, Guimarães R, Mattevi VS, Lazzaretti RK, Sprinz E, et al. (2011) The role of mannose-binding lectin gene polymorphisms in susceptibility to HIV-1 infection in Southern Brazilian patients. AIDS 25: 411-418. doi:10.1097/QAD.0b013e328342fef1. PubMed: 21192229.
32. Finocchario-Kessler S, Catley D, Berkley-Patton J, Gerkovich M, Williams K, et al. (2011) Baseline predictors of ninety percent or higher antiretroviral therapy adherence in a diverse urban sample: the role of patient autonomy and fatalistic religious beliefs. AIDS Patient Care STDs 25: 103-111. doi:10.1089/apc.2010.0319. PubMed: 21235403.
33. Yi T, Cocohoba J, Cohen M, Anastos K, DeHovitz JA, et al. (2011) The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women. J Acquir Immune Defic Syndr 56: 253-262. doi:10.1097/QAI.0b013e31820a9d04. PubMed: 21239994.
34. Bassett IV, Chetty S, Giddy J, Reddy S, Bishop K, et al. (2011) Screening for acute HIV infection in South Africa: finding acute and chronic disease. HIV Med 12: 46-53. doi:10.1111/j.1468-1293.2010.00850.x. PubMed: 20553336.
35. Mitchell C, Hitti J, Paul K, Agnew K, Cohn SE, et al. (2011) Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retrovir 27: 35-39. doi:10.1089/aid.2010.0129. PubMed: 20929397.
36. Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, et al. (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25: F7-12. doi:10.1097/QAD.0b013e328345766f. PubMed: 21412057.
37. Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J, (2011) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Med 12: 157-165. doi:10.1111/j.1468-1293.2010.00864.x. PubMed: 20722752.
38. Lartey M, Sagoe KW, Yang H, Kenu E, Xexemeku F, et al. (2011) Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen. Clin Infect Dis 52: 547-550. doi:10.1093/cid/ciq196. PubMed: 21252140.
39. Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, et al. (2011) A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 25: 57-63. doi:10.1097/QAD.0b013e32833f9f63. PubMed: 21076278.
40. Waters L, Fisher M, Winston A, Higgs C, Hadley W, et al. (2011) A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 25: 65-71. doi:10.1097/QAD.0b013e328341685b. PubMed: 21099666.
41. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, et al. (2011) HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 56 (Suppl 1):: S22-S32. doi:10.1097/QAI.0b013e318209751e. PubMed: 21317590.
42. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, et al. (2011) Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 56 (Suppl 1):: S33-S38. doi:10.1097/QAI.0b013e3181fcbcb4. PubMed: 21317592.
43. Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, et al. (2011) Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr 56 (Suppl 1):: S83-S90. doi:10.1097/01.qai.0000397379.23943.e1. PubMed: 21317600.
44. Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, et al. (2011) Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr 56 (Suppl 1):: S39-S45. doi:10.1097/QAI.0b013e3182055138. PubMed: 21317593.
45. Sullivan LE, Botsko M, Cunningham CO, O'Connor PG, Hersh D, et al. (2011) The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr 56 (Suppl 1):: S54-S61. doi:10.1097/01.qai.0000397320.40083.fa. PubMed: 21317595.
46. Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, et al. (2011) Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr 56 (Suppl 1):: S62-S67. doi:10.1097/01.qai.0000397336.79987.d8. PubMed: 21317596.
47. Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, et al. (2011) Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 52: 138-146. doi:10.1093/cid/ciq056. PubMed: 21148532.
48. Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, et al. (2011) Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 25: 177-183. doi:10.1097/QAD.0b013e328341afa8. PubMed: 21150561.
49. Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, et al. (2011) Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 52: 248-256. doi:10.1093/cid/ciq104. PubMed: 21288852.
50. Linas BS, Minkoff H, Cohen MH, Karim R, Cohan D, et al. (2011) Relative time to pregnancy among HIV-infected and uninfected women in the Women's Interagency HIV Study, 2002-2009. AIDS 25: 707-711. doi:10.1097/QAD.0b013e3283445811. PubMed: 21297418.
51. Agwu AL, Jang SS, Korthuis PT, Araneta MR, Gebo KA, (2011) Pregnancy incidence and outcomes in vertically and behaviorally HIV-infected youth. JAMA 305: 468-470. doi:10.1001/jama.2011.79. PubMed: 21285423.
52. Westreich D, Maskew M, Rubel D, Macdonald P, Jaffray I, et al. (2012) Incidence of pregnancy after initiation of antiretroviral therapy in South Africa: a retrospective clinical cohort analysis. Infect Dis Obstet Gynecol, 2012(2012): 917059. PubMed: 22778536.
53. UNAIDS/WHO (2007) Ethical considerations for biomedical HIV prevention trials: guidance document. Available: http://data.unaids.org/pub/manual/2007/jc1349_ethics_2_11_07_en.pdf. Accessed 2 August 2013.
54. CONSORT (2007). tem: pp. 4a Eligibility criteria for participants. Geneva.
55. Ndekha MJ, van Oosterhout JJ, Zijlstra EE, Manary M, Saloojee H, et al. (2009) Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial. BMJ 338: b1867. doi:10.1136/bmj.b1867. PubMed: 19465470.
56. CDC (2012) HIV in the United States: At A Glance. Available: http://www.cdc.gov/hiv/resources/factsheets/us.htm.
57. UNAIDS (2012) Women, girls, gender equality and HIV. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/factsheet/2012/20120217_FS_WomenGirls_en.pdf.
58. WomensHealth.gov (2011) AIDS worldwide. http://www.womenshealth.gov/hiv-aids/aids-worldwide/.
59. UNAIDS (2010) Mother-to-child transmission of HIV data and statistics. Available: http://www.who.int/hiv/topics/mtct/data/en/index1.html.
60. UNAIDS (2012) Global Fact Sheet, World AIDS Day 2012. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_FactSheet_Global_en.pdf.